The acute adaptive mechanisms serve mainly to provide an adequate myocardial energy supply, whereas the chronic mechanisms compensate for long lasting unfavourable influencesfor example, by structural remodelling.
Physiological adaptive and compensatory mechanisms ACUTE MECHANISMS
It is not the aim of this article to provide a comprehensive list of all the numerous adaptive mechanisms operating in the heart. Some of the fundamental principles that underlie four main criteria will be discussed: * Regulation of oxygen supply above the critical range * Instantaneous adaptation of metabolic flow rates to current demands * High reserve capacity of vitally important ftunctions * Multistage control of important protective and adaptive mechanisms
Regulation of oxygen supply above the critical range The working heart depends exclusively on aerobic energy production. Myocardial oxygen reserve is very low-only 0 5 vol % is bound to myoglobin. Furthermore, even under resting conditions the heart extracts most of the oxygen provided by the coronary system, as indicated by a coronary venous Po2 of only 20 Hibernating myocardium Hibernation is a mechanism to protect against chronic myocardial ischaemia. It is a reversible state of impaired myocardial function at rest that reduces metabolic demands." Although hibernation may reduce and/or delay cellular injury and myocardial necrosis in the ischaemic region of the heart, the loss of con-tractile myocytes in the hibernating myocardium increases the load on the residual normal myocardium.
In contrast to the acute adaptive mechanisms, the chronic compensatory mechanisms, therefore, evoke not only beneficial cardioprotective effects but also unwanted side effects. The ratio of favourable cardioprotective effects to deleterious side effects depends on the activation of the compensatory mechanism. Generally, the more a compensatory mechanism is activated the more severe are its deleterious consequences.
Therapeutic approaches Like the physiological adaptive and compensatory mechanisms, treatments too can be acute or chronic. ACUTE 
INTERVENTIONS
The major aim of acute interventions is to prevent the loss of functional myocardium and thus preserve ventricular function. Acute interventions include the restoration of coronary perfusion by thrombolysis and/or percutaneous transluminal angioplasty in acute myocardial infarction or prosthetic valve replacement in severe aortic stenosis. Detrimental effects result only from unwanted side effects or complications but not from the treatment itself.
Artificial cardiac arrest during cardiac surgery is a special form of cardioprotection. Experimental and clinical data have established that cardioplegia has cardioprotective effects. These include limitation of myocardial damage, which reduces postoperative mortality and complications and improves long term 23 prognosis. CHRONIC 
Chronic interventions include long term pharmacotherapy, mainly in patients with congestive heart failure and/or coronary heart disease.
Congestive heart failure In patients with impaired left ventricular function ACE inhibitors have been shown not only to reduce mortality but also to prevent the transition to severe congestive heart failure. '7 According to the results of Veterans Heart Failure Trial (V-HeFT) I pure peripheral vasodilatation produced by the combination of hydralazine and isosorbide dinitrate significantly reduced mortality.24 This positive effect, however, was more pronounced when ACE inhibitors were used, as shown in V-HeFT II.25 The beneficial effect of ACE inhibitors has, therefore, to be based on additional mechanisms as well as afterload reduction by pure peripheral vasodilatation. Pure vasodilators, such as hydralazine, increase sympathetic activity: ACE inhibitors, however, do not have this unwanted side effect. 26 The results of trials with vasodilating ,B adrenoceptor blockers reinforce the importance of sympathetic stimulation in congestive heart failure. In a recent prospective randomised multicentre trial carvedilol, a ,B adrenoceptor blocker with a adrenoceptor blocking properties reduced mortality in heart failure patients who were already being treated with an ACE inhibitor by 67%. The Data and Safety Monitoring Board recommended premature termination of this study.27
Coronary heart disease The treatment of patients with coronary heart disease can be evaluated by: * Improvement of symptoms-that is, relief of angina * Reduction of myocardial ischaemia, mainly based on the reduction of ST segment depression during stress electrocardiography * Improvement in prognosis-that is, a reduction in mortality. Three major classes of anti-ischaemic drugs are currently used in patients with coronary heart disease-these are nitrates, calcium channel blockers, and ,B adrenoceptor blockers. Their efficacy in ameliorating symptoms and reducing the incidence of myocardial ischaemia is well established. However, they have different effects on outcome. These have been reviewed elsewhere. 28 There are few studies of nitrates and these were of small numbers of patients. Furthermore, some of the studies were evaluated retrospectively. In essence, the data obtained with nitrates do not convincingly demonstrate improvement in prognosis.
In theory calcium channel blockers should have cardioprotective effects. In patients with unstable angina and with acute myocardial infarction, however, all studies were negative; as were studies of nifedipine, diltiazem, and verapamil. Studies of secondary prevention during the post-infarction period were also negative, except for three studies of a subgroup of patients without signs of heart fail- The lack of an effect on outcome of calcium channel blockers-especially those of the nifedipine type-is probably related to their reflex activation of sympathetic activity, as shown by the increase in plasma catecholamines and heart rate. 28 The idea that the cardioprotective effects of ,B adrenoceptor blockers are directly related to their antiadrenergic properties is supported by two clinical findings: * Improvement of prognosis applies only to /B adrenoceptor blockers without intrinsic sympathetic activity. * During the post-infarction period the cardioprotective effect of }6 adrenoceptor blocking agents-that is, reduction of reinfarction-is directly related to their reduction in heart rate-that is, their antiadrenergic efficacy.29 Chronic cardioprotective interventions by pharmacotherapy in patients with congestive heart failure and coronary heart disease cannot be exclusively explained by haemodynamic effects. Outcome is improved by other pharmacological effects, such as inhibition of the sympatho-adrenergic system and of the reninangiontensin-system.
